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Introduction
Prostate cancer (PCa) is the second-leading cause of cancer death in men in the United States. The androgen receptor (AR) plays a central role in PCa, and the standard treatment for metastatic PCa is androgen deprivation therapy by medical or surgical castration. Although most patients initially respond, they invariably relapse despite castrate androgen levels (castration-resistant prostate cancer, CRPC). Previous studies have identified increased intratumoral androgen synthesis from precursor steroids generated by the adrenal glands, or possibly de novo androgen synthesis from cholesterol, as a mechanism of castration resistance (1) (2) (3) (4) (5) (6) . CYP17A1 is the critical enzyme required for the conversion of C21 steroids to C19 steroids such as DHEA that can be further reduced to the potent androgens testosterone and dihydrotestosterone (DHT). CYP17A1 inhibitors can thereby further markedly decrease the levels of residual androgens and precursor steroids that remain after castration, and the CYP17A1 inhibitor abiraterone is now approved by the FDA for treatment of CRPC (7, 8) . The direct AR antagonist enzalutamide has also recently been approved for treatment of CRPC (9, 10) . Previous AR antagonists used for PCa (flutamide, nilutamide, and bicalutamide) do not effectively prevent AR binding to chromatin and may thereby have weak agonist properties that limit their efficacy in CRPC (11) (12) (13) . In contrast, the enzalutamide liganded AR does not bind to chromatin, making this drug a purer AR antagonist with improved efficacy in CRPC (10) . However, the survival advantages for abiraterone and enzalutamide therapy in CRPC postchemotherapy are only about 4 months (7, 9) , and mechanisms of intrinsic or acquired resistance to these agents remain to be established (14) .
Galeterone (previously known as VN/124-1 or TOK-001) was developed as a CYP17A1
inhibitor, but similar to related compounds it has AR antagonist activity and was also found to promote AR degradation (15) (16) (17) . However, its effects on AR binding to chromatin have not been examined. Moreover, further studies indicated that galeterone at high concentrations could induce an endoplasmic reticulum (ER) stress response (18) and may decrease AR translation through direct or indirect effects on mTOR (19) , suggesting that some of its effects on AR expression may be indirect. Galeterone is currently in phase II clinical trials for CRPC, and responses in these trials may be related to both its activities towards CYP17A1 and its direct effects on AR. Therefore, this study was undertaken to determine the molecular basis for galeterone actions as a direct AR antagonist and for its effects on AR protein expression.
Materials and Methods

Cell culture and immunoblot analyses
LNCaP, VCaP, LAPC4, CWR22RV1, PC3 and HEK293T cells were purchased from American Type Culture Collection (ATCC, Manassas, VA). LAPC4-CR and C4-2 cells were derived from castration resistant xenografts of LAPC4 and LNCaP, respectively. Cells were cultured in RPMI1640 bovine serum (FBS). Androgen-deprivation was conducted by culturing cells in RPMI1640 or DMEM supplemented with 5% charcoal-dextran stripped serum (CSS) for at least 48 hours.
Whole cell lysates (WCL) were prepared using lysis buffer containing 2% SDS and subjected to immunoblotting. Nuclear and cytoplasmic fractions of the cell were prepared using the NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific, Waltham, MA) following manufacturer's instructions. The antibody against human AR (N20) and lamin A/C was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The antibody against V5 epitope tag was from Invitrogen (Carlsbad, CA). Antibodies against -actin (AC-15) and β-tubulin were from Millipore (Billerica, MA). Antibody against prostate specific antigen (PSA) was from Meridian Life Science (Memphis, TN). Antibodies against eIF2 and phospho-eIF2 were from Cell Signaling (Danvers, MA). The results from a minimum of two experiments were subjected to densitometry and normalized to -actin or β-tubulin loading control and the mean values relative to vehicle control (set to 1.0) given.
Recombinant DNA and stable cell lines
The AR-WT, T878A and W742C cDNA were subcloned from previously described constructs (20, 21) to pCMV-3xFLAG vector and to pDONR223 entry vector. For AR-F877L mutant, sitedirected mutagenesis using pDONR223-AR-WT as template was performed. The primer sets used were: sense 5'-cgagagagctgcatcagctcacttttgacctgcta-3', antisense 5'-tagcaggtcaaaagtgagctgatgcagctctctcg-3'. pLenti6.3 lentiviral expression vectors carrying AR-WT, T878A or F877L mutant sequences were then generated using the Gateway Cloning System 
Results
Galeterone functions directly as an AR antagonist
We first examined the effects of galeterone on AR signaling in PCa cells. Androgen- (Fig. 1B) . In contrast, abiraterone had minimal effects, consistent with galeterone directly suppressing basal AR activity in these cells independently of its CYP17A1 inhibitor activity. As expected, treatment with DHT was able to partially rescue PSA expression repressed by galeterone or enzalutamide.
Bicalutamide more modestly decreased PSA expression in both cell lines treated with DHT, but did not decrease basal PSA levels in the absence of ligand, consistent with it being a less potent AR antagonist with weak partial agonist activity.
The antagonist activity of galeterone was further assessed using COS-7 cells cotransfected with an AR expression construct and a luciferase reporter driven by 4 consecutive 
Galeterone impairs AR binding to chromatin
An important distinction between bicalutamide and enzalutamide is that the bicalutamide liganded AR can associate with chromatin, which may contribute to weak partial agonist activity (10, 12) . To test whether galeterone stimulates AR binding to DNA, we used a plasmid encoding the full-length AR fused to the VP16 transactivation domain (VP16-AR), which can stimulate transcription independently of coactivator recruitment by AR. COS-7 cells were transfected with this plasmid and with the ARE4-LUC reporter construct, and then stimulated with a series of ligands ( Fig. 2A) . As a positive control, DHT induced ARE-LUC activity in a dose-dependent fashion, indicating the binding of VP16-AR to the ARE4-LUC construct ( Fig. 2A) . As we showed previously, the VP16-AR similarly could be stimulated by bicalutamide, indicative of AR binding to the reporter gene (12) . In contrast, also as shown previously, enzalutamide did not stimulate the VP16-AR (10). Significantly, galeterone similarly failed to activate the VP16-AR, indicating that it does not support DNA binding. 
Galeterone does not directly enhance degradation of wildtype AR
The unliganded AR is degraded by a proteasome dependent pathway, and its stability is increased by androgen binding (22) (23) (24) . Galeterone has been shown previously to decrease AR protein expression in PCa cell lines (LNCaP and LAPC4) and in LAPC4 xenografts (16, 17) .
However, these decreases in AR protein and increases in AR degradation may in part be due to competitive displacement of androgen from the AR ligand domain by galeterone. Moreover, galeterone at higher concentrations (generally over 10 M) has been reported to activate cellular stress pathways that may indirectly decrease AR protein expression (18, 19) . Therefore, to determine whether galeterone binding to the AR could directly enhance AR degradation, we assessed the effects of galeterone at up to 10 M in androgen-deprived cells. Importantly, based on the results in figure 1, we anticipate that most of the AR would be liganded to galeterone at 10 M, so that effects at higher concentration would be indirect and mediated by off-target mechanisms.
In one set of experiments we used LAPC4 cells and its subline LAPC4-CR cells, which both express wildtype AR. The LAPC4-CR line was established from a relapsed castrationresistant LAPC4 xenograft. The cells were cultured in androgen-depleted medium for 48 hours and then treated with galeterone at 0.5-10 M for 24 hours. In LAPC4 cells, galeterone at concentrations of 0.5-5 M did not lead to decreased AR expression, but did lead to a 48% decrease at 10 M (Fig. 3A) . To more directly assess AR protein stability, we then treated the androgen-deprived and vehicle or galeterone stimulated LAPC4 cells with cycloheximide (CHX) to block new protein synthesis. Significantly, the rate at which AR protein decayed in these cells was not altered by the treatment with galeterone compared to vehicle control (Fig. 3B) . In LAPC4-CR cells, galeterone had no clear effect on overall AR protein levels or stability ( Fig. 3C and D).
We next similarly examined VCaP cells, which express an amplified wildtype AR. In androgen-deprived VCaP cells, galeterone led to a moderate decrease of AR protein levels (Fig.   3E ). However, as there is substantial de novo androgen synthesis in VCaP cells (2), any decrease in AR protein may reflect decreased intracellular androgen levels due to the inhibition of CYP17A1 by galeterone. To clarify whether any decrease in AR expression is a direct effect of galeterone on AR rather than an indirect effect via its CYP17A1 activity, we treated VCaP cells with abiraterone at up to 5 M, which effectively blocks CYP17A1 activity in these cells (2 
to the abiraterone did modestly decrease AR protein, suggesting a direct effect of galeterone on AR (Fig. 3F) . The addition of galeterone at 10 M to the abiraterone similarly decreased AR protein in VCS2 cells, which were derived from a castration-resistant VCaP xenograft (2).
However, when we next used cycloheximide treatment to directly assess for effects of galeterone on AR stability in VCaP cells, we found that galeterone at 10 M did not increase the rate of AR degradation (Fig. 3G) . Based on these results, we conclude that galeterone at concentrations up to 10 M does not substantially enhance AR degradation in VCaP cells, but may decrease AR protein by indirect mechanisms at higher concentrations or in combination with other agents.
Similar results were obtained when we examined CWR22Rv1 cells. The AR in the parental CWR22 cells has a mutation in codon 875 that broadens its ligand specificity, and the CWR22Rv1 cells have in addition a duplication of exon 3 encoding the DNA binding domain (25). These cells also express an alternatively spliced AR isoform that deletes the ligand binding domain (26) . As observed in VCaP cells, AR protein was slightly decreased at 10 M galeterone, while bicalutamide, enzalutamide or abiraterone treatment did not change AR levels (Fig. 3H ).
As expected, the full length AR protein was slightly increased by DHT, with no clear effect on the AR splice variant (AR-V). Overall, these results indicate that galeterone does not have marked direct effects on AR protein stability, but may decrease AR protein by indirect mechanisms at concentrations at or above 10 M.
Galeterone markedly enhances AR protein degradation in LNCaP and C4-2 cells
In contrast to the results above, galeterone at concentrations well below 10 M in androgen-deprived C4-2 cells markedly decreased AR protein (Fig. 4A) . This decrease was from 36-87% at 0.5-10 M, while there was no decrease in AR protein with abiraterone at 2.5 or 5 M (Fig. 4A) 
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decreased the half-life of endogenous AR in androgen-deprived C4-2 cells from ~6 hours to ~2 hours (Fig. 4B) . The parental line of C4-2, LNCaP, was also tested. Galeterone at 5 or 10 M similarly dramatically decreased AR protein expression in androgen-deprived LNCaP cells (Fig.   4C ), and treatment with cycloheximide showed that galeterone was increasing AR degradation in these cells (Fig. 4D) .
To confirm that the decrease in AR protein was through proteasome mediated degradation, we used a proteasome inhibitor, MG132. Treatment of LNCaP cells with MG132 prevented the decrease in AR protein expression caused by galeterone (Fig. 4E) . To determine whether the effects of galeterone were direct and mediated by AR binding, we also assessed whether DHT could prevent the decline in AR protein. As shown in figure 4F , DHT could partially block the galeterone mediated decrease in AR protein.
Finally, as galeterone has been reported to induce an ER stress response that may indirectly affect AR expression (18), we addressed whether galeterone treatment in these cells was inducing an ER stress response. The ER stress response was assessed based on phosphorylation of eukaryotic initiation factor 2 (eIF2). Consistent with a previous report (18) , an ER stress response could be induced by galeterone, which we observed at 20 M (Fig. 4G ).
However, galeterone at 10 M, which still markedly reduced AR protein, did not induce this stress response. These results together indicate that galeterone is directly enhancing AR protein degradation in LNCaP and C4-2 cells.
Galeterone enhances degradation of the T878A mutant AR
The marked effects of galeterone on AR protein expression in the C4-2 and LNCaP cells could reflect their T878A mutant AR or other distinct features of these cell lines such as their PTEN deficiency. To initially address the role of the T878A mutation, LNCaP cells were transfected with a construct coding for FLAG-tagged wildtype AR and geneticin resistance, and short-term geneticin resistant cells were selected. These cells were then androgen-deprived for 48 hours and treated with galeterone for 24 hours at increasing doses. Expression of ectopic wildtype AR was probed using anti-FLAG antibody. No decrease in the expression of ectopic wildtype AR was observed at up to 10 M galeterone, while the endogenous T878A AR protein in the parental LNCaP cells was decreased (Fig. 5A ).
To rule out the possible confounding effect of the ectopic expression vector versus the endogenous AR, we established PC3 stable cells using lentiviral vectors expressing AR WT or AR T878A. Treatment of these stable PC3 cells with galeterone led to a ~30% decrease in AR WT, but the decrease in AR T878A was substantially greater (~70%) (Fig. 5B) . To further validate this result, LNCaP stable cells expressing epitope-tagged AR WT or T878A were also established. Similar to the PC3 stable cells, galeterone substantially decreased AR T878A expression, with minimal effect on AR WT levels (Fig. 5C ).
The T878A AR can be strongly stimulated by the AR antagonists hydroxyflutamide and nilutamide. Therefore, we also tested whether galeterone enhances degradation of AR with other known mutations that can mediate resistance to AR antagonists such as enzalutamide or bicalutamide. Recent reports have found that enzalutamide can activate a F877L mutant AR (27) (28) (29) . However, in contrast to the transfected T878A AR, galeterone did not decrease expression of the F877L mutant AR (Fig. 5D) . Similarly, we found that expression of the W742C mutant AR, which is stimulated by bicalutamide, was not decreased by galeterone ( Figure 5E ).
Taken together, these results show that galeterone markedly and directly enhances degradation of the T878A mutant AR, while having only modest effects on expression of wildtype AR that may be cell line dependent and through direct or indirect mechanisms. Galeterone suppresses AR activity both by functioning as a CYP17A1 inhibitor and by binding directly to AR (15, 16) . It has clear activity against AR dependent PCa cells in vitro and in xenograft models, and its efficacy in patients is currently being assessed in phase 2 clinical trials. However, the molecular basis for its direct effects on AR remains to be fully established.
In this study we confirmed that galeterone functions as a direct AR competitive antagonist.
Moreover we found that galeterone, in contrast to bicalutamide but similar to enzalutamide, does not stimulate AR binding to chromatin. Previous studies have shown that bicalutamide functions as an AR antagonist because it does not effectively recruit coactivator proteins and may instead recruit corepressors (12, 30) . However, this antagonist activity may be circumvented in CRPC through several mechanisms, such as increased AR or alterations in transcriptional coactivator or corepressor proteins, which may enhance the weak partial agonist activity of bicalutamide (14) . In contrast, enzalutamide has a distinct mechanism of action as it does not stimulate AR binding to chromatin, which makes it a purer antagonist and likely contributes to its efficacy in CRPC (10) . Therefore, our findings suggest that galeterone will function similar to enzalutamide in CRPC as a relatively pure direct AR antagonist, which in conjunction with its activity as a CYP17A1 inhibitor may enhance the ability of galeterone to suppress AR function in CRPC.
Previous studies have also shown that galeterone treatment can decrease AR protein levels and may increase AR protein degradation (16) . However, it has not been clear whether this is due to direct effects on AR, as galeterone at higher concentrations (~20 M) has been found to induce an ER stress response (18) , and to decrease phosphorylation of 4EBP1, possibly reflecting decreased TORC1 activity (19) . Using galeterone at lower concentrations (up to 10 M) that could effectively suppress DHT stimulated AR activity, but did not stimulate a stress response, we found that galeterone did not substantially enhance degradation of wildtype AR in androgen starved LAPC4 or VCaP PCa cells. In contrast, degradation of the T878A 
mutant AR, which is expressed by LNCaP and C4-2 cells, was markedly increased by a proteasome-dependent mechanism in response to galeterone binding.
These findings are consistent with previous data showing that galeterone at 5-10 M could decrease AR protein expression in LNCaP cells in vitro (16) . While galeterone has also been found previously to decrease AR protein in LAPC4 cells in vitro, this effect was observed at higher galeterone concentrations (15-20 M) that may have decreased AR expression by indirect mechanisms (16) . Significantly, in vivo studies using LAPC4 xenografts have shown marked decreases in AR protein in response to galeterone (16, 17) . Our in vitro data certainly do not rule out the possibility that galeterone binding may directly enhance AR degradation in vivo due to displacement of an endogenous ligand and/or subtle differences in mechanisms regulating AR degradation in vivo versus in vitro. Alternatively, the decreased AR protein in vivo may be mediated by indirect mechanisms, or possibly synergy between direct and indirect mechanisms. Finally, a recent study found that galeterone and related compounds could enhance degradation of the full-length AR and truncated AR (ligand-binding domain deleted) in CWR22Rv1 cells, further establishing that galeterone has a mechanism of action that is independent of binding to the AR ligand-binding domain (31) .
Structural studies have shown that T878 in helix 9 of the AR ligand-binding domain sits in the steroid-binding pocket and that the T878A mutation provides more room in this pocket (32, 33) . As a result, binding of the AR antagonist hydroxyflutamide to the T878A mutant AR does not distort the ligand-binding pocket and this drug thereby functions as potent agonist of the T878A AR (34) . Galeterone is a steroidal compound modified with a bulky benzimidazole group at the C17 position, which in DHT has an hydroxyl group that contacts T878. However, as galeterone is still an antagonist for the T878A AR, it is apparent that the benzimidazole group must still distort the ligand binding pocket. Nonetheless, we propose that the T878A mutation alters the positioning of helix 9 in the galeterone liganded AR, and may thereby enhance the 
ubiquitylation of one or more helix 9 lysines by an E3 ubiquitin ligase that normally mediates degradation of the unliganded AR, or that mediates turnover of the agonist-liganded AR.
Alternatively, the galeterone-liganded T878A mutant AR may be degraded through a distinct mechanism that does not normally mediate AR degradation. In either case, these findings demonstrate that certain conformations of AR can markedly enhance its degradation, and support efforts to identify novel antagonists that can similarly alter the structure of wild-type AR and thereby enhance its degradation. 
